LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

Search

Harmony Biosciences Holdings Inc

Open

SectorHealthcare

38.06 0.74

Overview

Share price change

24h

Current

Min

37.36

Max

38.18

Key metrics

By Trading Economics

Income

-5.8M

40M

Sales

16M

200M

P/E

Sector Avg

12.071

35.724

EPS

0.92

Profit margin

19.839

Employees

268

EBITDA

3M

59M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+33.38% upside

Dividends

By Dow Jones

Next Earnings

28 paź 2025

Market Stats

By TradingEconomics

Market Cap

112M

2.2B

Previous open

37.32

Previous close

38.06

News Sentiment

By Acuity

50%

50%

172 / 372 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Harmony Biosciences Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 sie 2025, 22:51 UTC

Earnings

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 sie 2025, 23:57 UTC

Earnings

Trip.com Group 1H Rev $4.01B

27 sie 2025, 23:57 UTC

Earnings

Trip.com Group 1H Adj EPS $1.84

27 sie 2025, 23:57 UTC

Earnings

Trip.com Group 1H EPS $1.82

27 sie 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 sie 2025, 23:39 UTC

Earnings

Correction to Nvidia Earnings Article -- WSJ

27 sie 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 sie 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 sie 2025, 22:58 UTC

Earnings

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 sie 2025, 22:57 UTC

Earnings

South32 FY Free Cash Flow $192 Million

27 sie 2025, 22:56 UTC

Earnings

South32 FY Total Capital Expenditure $1.35 Billion

27 sie 2025, 22:56 UTC

Earnings

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 sie 2025, 22:55 UTC

Earnings

South32 Net Cash $123 Million at June 30

27 sie 2025, 22:54 UTC

Earnings

South32: Focused on Maintaining Strong Operating Momentum

27 sie 2025, 22:53 UTC

Earnings

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 sie 2025, 22:53 UTC

Earnings

South32 Extends Capital Management Program for 12 Months

27 sie 2025, 22:52 UTC

Earnings

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 sie 2025, 22:51 UTC

Earnings

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 sie 2025, 22:51 UTC

Earnings

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 sie 2025, 22:50 UTC

Earnings

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 sie 2025, 22:50 UTC

Earnings

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 sie 2025, 22:45 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 sie 2025, 22:44 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 sie 2025, 22:44 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 sie 2025, 22:43 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 sie 2025, 22:43 UTC

Earnings

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 sie 2025, 22:42 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 sie 2025, 22:42 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 sie 2025, 22:40 UTC

Earnings

Sandfire Resources Net Debt $123 Million at June 30

27 sie 2025, 22:40 UTC

Earnings

Sandfire Resources FY Underlying Ebitda $527.7 Million

Peer Comparison

Price change

Harmony Biosciences Holdings Inc Forecast

Price Target

By TipRanks

33.38% upside

12 Months Forecast

Average 50.75 USD  33.38%

High 70 USD

Low 33 USD

Based on 9 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

8

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

29.8 / N/ASupport & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Very Strong Bearish Evidence

Sentiment

By Acuity

172 / 372 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.